Sociedad Americana de Hirudoterapia

Изпълнителна агенция по лекарствата — Bulgarian Drug Agency

BDA · Bulgaria · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Bulgaria's Bulgarian Drug Agency — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Bulgarian national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Bulgaria
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Bulgarian Medicinal Products in Human Medicine Act (Закон за лекарствените продукти в хуманната медицина)
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Bulgarian law
  • Bulgarian Medical Devices Act (Закон за медицинските изделия)

Prescriber Requirements

  • Bulgarian Medical Association (Български лекарски съюз)–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

BDA registration as applicable; Bulgarian-language (Cyrillic script) labelling required by national law. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; Bulgarian Food Safety Agency clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

National Health Insurance Fund (НЗОК) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Bulgarian law. BDA coordinates with EMA and other EU NCAs; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.